A Phase 1 Single Dose Escalation Study Evaluating the Safety and Tolerability ofVX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTRGenotype Not Responsive to CFTR Modulator Therapy

Project: Research project

Project Details

Description

A Phase 1 Single Dose Escalation Study Evaluating the Safety and Tolerability of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy
StatusActive
Effective start/end date10/1/2210/1/24

Funding

  • VERTEX PHARMACEUTICALS INCORPORATED

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.